心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Cancer: β受体阻滞剂并不降低结直肠癌风险

2012-05-16 medsci 生物谷

β受体阻滞剂结直肠癌去甲肾上腺素降压药
关注

       一项新的研究发现，与当前血压药物能防止结直肠癌相反，服用β-受体阻滞剂治疗高血压并不减少一个人发展罹患结直肠癌的风险。相关研究论文发表在Cancer杂志上，该研究还表明即使长期使用β受体阻滞剂的亚型并无明显减少大肠癌的危险。        近年来，研究者们认为β受体阻滞剂的服用可能与癌症的风险降低有

       一项新的研究发现，与当前血压药物能防止结直肠癌相反，服用β-受体阻滞剂治疗高血压并不减少一个人发展罹患结直肠癌的风险。相关研究论文发表在Cancer杂志上，该研究还表明即使长期使用β受体阻滞剂的亚型并无明显减少大肠癌的危险。

       近年来，研究者们认为β受体阻滞剂的服用可能与癌症的风险降低有关。这个理论源于动物实验研究和实验室研究中发现应激激素去甲肾上腺素能促进癌细胞的生长和扩散。β受体阻滞剂抑制去甲肾上腺素，所以认为它能具有抗癌特性。

        β-受体阻滞剂对结直肠癌风险的影响在先前的一些研究中实际上得出了不一致的结果。为了更深入解决这一问题，德国癌症研究中心的Michael Hoffmeister博士和他的同事们对2003年至2007年与1762例大肠癌和1708未患癌症的人进行了随访研究。

       考虑某些病人特征（如体重和吸烟状况）和其他可能影响结果的因素后，研究人员并没有发现使用β受体阻滞剂和结直肠癌风险降低之间的联系。总的来说，这项研究结果并不支持降血压药物防止结直肠癌这一假设。 

拓展阅读：

JCO：β受体阻滞剂改善乳腺癌患者RFS而非OS

JCO：β受体阻滞剂普萘洛尔降低乳腺癌死亡率

原始链接：

Jansen L, et al.Beta blocker use and colorectal cancer risk: Population-based case-control study.Cancer. 2012 May 14. doi: 10.1002/cncr.26727. [Epub ahead of print]
 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061316, encodeId=b52d2061316dc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jun 27 19:16:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085680, encodeId=46dd2085680a5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Mar 05 02:16:00 CST 2013, time=2013-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705318, encodeId=afa31e0531801, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 16:16:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995096, encodeId=079c1995096fc, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Jul 01 02:16:00 CST 2012, time=2012-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274910, encodeId=b50912e4910ff, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452584, encodeId=464e14525841f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2012-06-27 sjq027

    #癌风险#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2061316, encodeId=b52d2061316dc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jun 27 19:16:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085680, encodeId=46dd2085680a5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Mar 05 02:16:00 CST 2013, time=2013-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705318, encodeId=afa31e0531801, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 16:16:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995096, encodeId=079c1995096fc, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Jul 01 02:16:00 CST 2012, time=2012-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274910, encodeId=b50912e4910ff, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452584, encodeId=464e14525841f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2013-03-05 zhyy88

    #阻滞剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2061316, encodeId=b52d2061316dc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jun 27 19:16:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085680, encodeId=46dd2085680a5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Mar 05 02:16:00 CST 2013, time=2013-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705318, encodeId=afa31e0531801, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 16:16:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995096, encodeId=079c1995096fc, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Jul 01 02:16:00 CST 2012, time=2012-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274910, encodeId=b50912e4910ff, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452584, encodeId=464e14525841f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2013-01-11 lfyang

    #结直肠癌风险#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2061316, encodeId=b52d2061316dc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jun 27 19:16:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085680, encodeId=46dd2085680a5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Mar 05 02:16:00 CST 2013, time=2013-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705318, encodeId=afa31e0531801, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 16:16:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995096, encodeId=079c1995096fc, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Jul 01 02:16:00 CST 2012, time=2012-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274910, encodeId=b50912e4910ff, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452584, encodeId=464e14525841f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2012-07-01 tulenzi

    #受体阻滞剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2061316, encodeId=b52d2061316dc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jun 27 19:16:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085680, encodeId=46dd2085680a5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Mar 05 02:16:00 CST 2013, time=2013-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705318, encodeId=afa31e0531801, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 16:16:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995096, encodeId=079c1995096fc, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Jul 01 02:16:00 CST 2012, time=2012-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274910, encodeId=b50912e4910ff, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452584, encodeId=464e14525841f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2012-05-18 muzishouyi

    #β受体阻滞剂#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2061316, encodeId=b52d2061316dc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jun 27 19:16:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085680, encodeId=46dd2085680a5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Tue Mar 05 02:16:00 CST 2013, time=2013-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705318, encodeId=afa31e0531801, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 16:16:00 CST 2013, time=2013-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995096, encodeId=079c1995096fc, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Jul 01 02:16:00 CST 2012, time=2012-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274910, encodeId=b50912e4910ff, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452584, encodeId=464e14525841f, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 10:16:00 CST 2012, time=2012-05-18, status=1, ipAttribution=)]
    2012-05-18 crystal0564

    #结直肠#

    0

相关资讯

儿童患者，如何选择β受体阻滞剂

作者：储晨 齐春华 刘芳（复旦大学附属儿科医院）        导语：β受体阻滞剂，是一类在儿童中亦有较广泛应用的药物，可用于多种疾病。但如何选择β受体阻滞剂还真是一门学问，本文着重阐述其在几种常见儿童疾病中的应用。       1、肥厚型心肌病：缓解症状，及早选择β受体阻滞剂    &

β受体阻滞剂治疗间歇性跛行合并动脉高血压

　德国一项双盲、随机对照研究显示，在治疗后约1年期间，β受体阻滞剂在间歇性跛行合并动脉高血压患者中的耐受性良好，直接比较奈必洛尔和美托洛尔对这类患者的疗效则无显著性差异。该研究于2011年6月6日在线发表于《高血压》（Hypertension）杂志。 　　β受体阻滞剂影响血管紧张度，因而在外周动脉疾病上的应用颇受争议。β受体阻滞剂奈必洛尔具有血管舒张、内皮依赖性和一氧化氮（NO）释放特性，可能

从PURE研究谈β受体阻滞剂对社区冠心病的二级预防

胡大一 教授        全世界患有心血管疾病（CVD）的人数超过1亿，每年全世界大约有3500万人发生1次急性冠状动脉事件或脑血管事件，其中约半数事件发生于已知有血管疾病的人群。     大量临床研究证实，有冠心病病史的人群服用二级预防药物，如抗血小板药物、β受体阻滞剂、血管紧张素转换酶抑制剂（ACEI）或血管紧张素受体拮抗剂